These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29257751)

  • 21. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera.
    Bolstad N; Warren DJ; Bjerner J; Kravdal G; Schwettmann L; Olsen KH; Rustad P; Nustad K
    Clin Chem Lab Med; 2011 Sep; 49(12):2001-6. PubMed ID: 21899496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma.
    Trimboli P; Lauretta R; Barnabei A; Valabrega S; Romanelli F; Giovanella L; Appetecchia M
    Int J Biol Markers; 2018 May; 33(2):156-160. PubMed ID: 29707993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer.
    Walter MA; Meier C; Radimerski T; Iten F; Kränzlin M; Müller-Brand J; de Groot JW; Kema IP; Links TP; Müller B
    Cancer; 2010 Jan; 116(1):31-40. PubMed ID: 19890958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterophilic antibodies interfering with radioimmunoassay. A false-positive pregnancy test.
    Vladutiu AO; Sulewski JM; Pudlak KA; Stull CG
    JAMA; 1982 Nov; 248(19):2489-90. PubMed ID: 6897083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can procalcitonin be useful for medullary thyroid cancer?
    Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
    Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procalcitonin as a marker of medullary thyroid carcinoma.
    Cancela-Nieto MG; Sánchez-Sobrino P; Velo-García A
    Minerva Endocrinol (Torino); 2021 Dec; 46(4):481-482. PubMed ID: 32720502
    [No Abstract]   [Full Text] [Related]  

  • 27. Heterophilic antibodies remain a problem for the immunoassay laboratory.
    Ward G; McKinnon L; Badrick T; Hickman PE
    Am J Clin Pathol; 1997 Oct; 108(4):417-21. PubMed ID: 9322595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
    Trimboli P; Giovanella L
    Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules.
    Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L
    Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterophilic antibody interference in a non-endogenous molecule assay: an apparent elevation in the tacrolimus concentration.
    Altinier S; Varagnolo M; Zaninotto M; Boccagni P; Plebani M
    Clin Chim Acta; 2009 Apr; 402(1-2):193-5. PubMed ID: 19150346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking.
    d'Herbomez M; Caron P; Bauters C; Do Cao C; Schlienger JL; Sapin R; Baldet L; Carnaille B; Wémeau JL;
    Eur J Endocrinol; 2007 Dec; 157(6):749-55. PubMed ID: 18057382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma.
    Takahashi K; Ozawa E; Nakao K; Aoki S; Takase Y
    J Gastroenterol Hepatol; 2019 Jun; 34(6):964. PubMed ID: 30663800
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypercalcitoninemia, nodular goiter, and pancreatic tumor.
    Ghnassia JP; Lindner V; Schneegans O; Haegelé P
    Thyroid; 1999 Jun; 9(6):599-600. PubMed ID: 10411123
    [No Abstract]   [Full Text] [Related]  

  • 34. False increase of cardiac troponin I with heterophilic antibodies.
    Fitzmaurice TF; Brown C; Rifai N; Wu AH; Yeo KT
    Clin Chem; 1998 Oct; 44(10):2212-4. PubMed ID: 9761264
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays.
    Preissner CM; Dodge LA; O'Kane DJ; Singh RJ; Grebe SK
    Clin Chem; 2005 Jan; 51(1):208-10. PubMed ID: 15613712
    [No Abstract]   [Full Text] [Related]  

  • 36. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer.
    Allelein S; Ehlers M; Morneau C; Schwartz K; Goretzki PE; Seppel T; Feldkamp J; Krieg A; Knoefel WT; Kuebart A; Haase M; Dringenberg T; Schmid C; Schott M
    Horm Metab Res; 2018 Jan; 50(1):23-28. PubMed ID: 29169190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Medullary thyroid carcinoma].
    Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
    Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-cell-derived calcitonin-free neuroendocrine carcinoma of the thyroid: the diagnostic importance of CGRP immunoreactivity.
    Nakazawa T; Cameselle-Teijeiro J; Vinagre J; Soares P; Rousseau E; Eloy C; Sobrinho-Simões M
    Int J Surg Pathol; 2014 Sep; 22(6):530-5. PubMed ID: 24599901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
    Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
    Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody multispecificity in immunoassay interference.
    Levinson SS
    Clin Biochem; 1992 Apr; 25(2):77-87. PubMed ID: 1623581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.